Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Florida’s KidCare
  • LGBTQ+ Youth Crisis Line
  • Device Coverage by Medicare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Florida’s KidCare
  • LGBTQ+ Youth Crisis Line
  • Device Coverage by Medicare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Apr 4 2024

Full Issue

Judge's Order Supports Challenger To Moderna In Covid Shot Patent Suit

Arbutus's case against Moderna was given some support by U.S. District Judge Mitchell Goldberg, who interpreted parts of the patents in Arbutus' favor. Also in the news: a Chinese drugmaker's Ozempic biosimilar; Walmart Health's health center expansion; and more.

Shares of Moderna (MRNA.O) fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines. ... In a so-called "claim construction order", U.S. District Judge Mitchell Goldberg interpreted parts of the patents in ways that strengthened Arbutus' case, rejecting Moderna's proposed definitions. (4/3)

A drugmaker in China has developed a biosimilar version of Novo Nordisk's (NOVOb.CO) popular diabetes drug Ozempic and applied for approval to sell it there, in a potential challenge to Novo's expansion plans in the country. Hangzhou Jiuyuan Gene Engineering said on Wednesday in a post on its official social media account that it was seeking approval to sell the drug, which it calls Jiyoutai, to control blood sugar in patients with type 2 diabetes. (Silver and Burger, 4/3)

Value-based care was thrust into the spotlight as Kaiser Permanente closed its acquisition of Geisinger Health, solidifying plans for a new network that will focus on creating more value for patients. Kaiser will fold Geisinger into a nonprofit entity it created called Risant Health, and there are plans to add several other health systems to the network within the next five years. (Hudson, 4/3)

Also —

Pacs Group, an operator of skilled care nursing facilities, filed plans for an initial public offering and seeks to raise almost $400 million. The company, which has more than 200 skilled nursing facilities and other post-acute operations across nine states, seeks to offer just over 19 million shares at a price between $20 to $22 per share, according to a filing this week with the Securities and Exchange Commission. (DeSilva, 4/3)

Walmart Health is pulling back on parts of its plan to open dozens of new health centers this year. The mega-retailer said last year it would add more than 30 health centers across four states in 2024, but that number has since been reduced to 22 in two states, a spokesperson said Wednesday. Walmart is set to open four health centers in the Houston area this month and will roll out more clinics throughout the summer and fall, the spokesperson said. (Hudson, 4/3)

The state Health Department has returned Mount Sinai’s hotly contested application to shutter Beth Israel, after regulators determined it was missing key information to support the stated rationale for the closure. Regulators also argued the private medical center failed to adequately prove availability of emergency care post-closure, according to court records made public Wednesday. (Kaufman, 4/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ